Botox-like drug without the needle is worth $20 million to Medicis



Botox / Scottsdale AZ Medical Spas


This article is brought to you by

The allure of a potential Botox rival that goes on the skin without needing to be injected persuaded Medicis Pharmaceuticals to pay $20 million for about 10 percent of Revance Therapeutics.

The deal, announced Dec. 11, also gives Medicis of Scottsdale, Ariz., an option to buy the Mountain View-based company or to acquire an exclusive license for Revance’s experimental botulinum-toxin wrinkle-fighter in North America when the drug completes Phase 2 clinical trials.

Botox, made by Allergan of Irvine, is the No. 1 cosmetic medical treatment in the country, at about 4 million injection treatments last year for people seeking to smooth the lines in their faces.

“The early stage technology of Revance’s novel delivery of botulinum toxin type A topically for aesthetic purposes is of particular interest to us for our aesthetic product pipeline,” said Jonah Shacknai, chief executive of Medicis. We believe the application of botulinum toxin type A without an injection could dramatically expand the usage of the treatment, and expand the market even more rapidly than it is growing today.”

Medicis makes the No. 1 dermal filler, Restylane, and is seeking U.S. Food and Drug Administration approval for its own injectable version of the botulinum toxin.

Revance says its technology lets large drug molecules penetrate the skin. The company has exclusive worldwide rights to a highly purified version of botulinum toxin type A with a low molecular weight, Revance says.



Sign up for the Spavelous Weekly Free Spa Magazine and read the latest on Medical Spa Treatments in the first two January issues.



Press Release




Find a medspa / Medical spas in

Spa Deals Finder